Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly pack could cut costs and fight child malnutrition

NCT ID NCT07540793

Prevention Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study in Ethiopia tests whether a new 7-day package of a nutritional supplement (SQ-LNS) works as well as the usual daily packets for preventing malnutrition in children aged 6-24 months. Researchers will compare how well families stick to using each package type over 8 weeks. The goal is to see if the new design is acceptable, safe, and leads to similar or better use, potentially lowering costs and improving distribution.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Small Quantity Lipid-based Nutrient Supplements (SQ-LNS)
What this could lead to
If successful, this could lead to cheaper, easier distribution of a supplement that helps prevent malnutrition in young children.
What could go wrong
This is a small, early-stage study focused on packaging and adherence, not on health outcomes. The new packaging may not be used as intended or could have safety issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria (must meet all): * Written informed consent from head of household * Household within the study area * Available for the full 8-week study period * 1 child aged 6-22 months in the household at time of enrollment * Child has MUAC ≥ 12.5cm * Child does not have any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines\*\* * Child is not allergic to peanuts, milk, or soy * Household does not have multiple children within the eligible age range Exclusion Criteria (any excludes): * Head of household declines to sign written informed consent * Household is outside of the study area * Not available for the full 8-week study period * House has either multiple children aged 6-22 months in the household at time of enrollment, or 0 children aged 6-22 months at time of enrollment * Child has MUAC \< 12.5cm * Child has any clinical complications requiring inpatient treatment or referral to the health post, according to Ethiopian malnutrition treatment guidelines * Child is allergic to peanuts, milk, or soy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Malnutrition, child are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Child Nutrition Disorders nutritional disorder nutritional deficiency disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Malnutrition, child Nutrition Prevention

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites in 3 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Debre Berhan University

    Debre Berhan, Ethiopia

  • Heidelberg University

    Heidelberg, Germany

  • Research Institute of Tropical Medicine

    Manila, Philippines

More trials for these conditions

Other studies related to the condition(s) this trial covers.